Shahneen Sandhu Mbbs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6539804/publications.pdf Version: 2024-02-01

		38742	16183
131	16,795	50	124
papers	citations	h-index	g-index
132	132	132	19029
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
2	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801.	27.0	1,441
3	Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 382, 2091-2102.	27.0	1,327
4	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	27.0	982
5	[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 825-833.	10.7	823
6	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 2017, 28, 368-376.	1.2	641
7	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 797-804.	13.7	552
8	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncology, The, 2013, 14, 882-892.	10.7	497
9	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 162-174.	10.7	450
10	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, 2019, 36, 385-401.e8.	16.8	359
11	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1348-1355.	1.6	343
12	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	9.4	341
13	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology, 2013, 24, 1807-1812.	1.2	310
14	Secondary mutations in <i><scp>BRCA2</scp></i> associated with clinical resistance to a <scp>PARP</scp> inhibitor. Journal of Pathology, 2013, 229, 422-429.	4.5	287
15	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. JAMA Oncology, 2020, 6, 519.	7.1	287
16	Dosimetry of ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Journal of Nuclear Medicine, 2019, 60, 517-523.	5.0	285
17	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.9	270
18	Envisioning the future of early anticancer drug development. Nature Reviews Cancer, 2010, 10, 514-523.	28.4	262

#	Article	IF	CITATIONS
19	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	13.7	240
20	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Annals of Oncology, 2012, 23, 2943-2947.	1.2	224
21	A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 1041-1050.	2.3	216
22	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	21.4	198
23	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 857-865.	5.0	191
24	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	10.7	183
25	Genomics of lethal prostate cancer at diagnosis and castration resistance. Journal of Clinical Investigation, 2020, 130, 1743-1751.	8.2	180
26	Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. Ca-A Cancer Journal for Clinicians, 2011, 61, 31-49.	329.8	178
27	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. European Urology Oncology, 2019, 2, 670-676.	5.4	134
28	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. Clinical Cancer Research, 2013, 19, 5485-5493.	7.0	126
29	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncology, The, 2012, 13, 1114-1124.	10.7	125
30	Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews Clinical Oncology, 2011, 8, 302-306.	27.6	120
31	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	10.7	120
32	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology, 2019, 30, 804-814.	1.2	117
33	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. European Journal of Cancer, 2010, 46, 9-20.	2.8	108
34	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2322-2327.	6.4	101
35	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology, 2018, 73, 687-693.	1.9	99
36	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. European Urology, 2013, 64, 300-306.	1.9	85

Shahneen Sandhu Mbbs

#	Article	IF	CITATIONS
37	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	7.3	81
38	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	1.9	80
39	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
40	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Research, 2014, 24, 504-508.	1.2	70
41	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. European Urology, 2022, 81, 364-372.	1.9	70
42	Genome-wide plasma DNA methylation features of metastatic prostate cancer. Journal of Clinical Investigation, 2020, 130, 1991-2000.	8.2	68
43	Cell cycle control as a promising target in melanoma. Current Opinion in Oncology, 2015, 27, 141-150.	2.4	67
44	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66
45	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2019, 116, 148-157.	2.8	64
46	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Annals of Oncology, 2013, 24, 1416-1418.	1.2	62
47	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ~†. Annals of Oncology, 2020, 31, 1075-1082.	1.2	62
48	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nature Reviews Urology, 2015, 12, 37-47.	3.8	60
49	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 5539-5552.	7.0	59
50	Prostate cancer cellâ€intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 2020, 21, e50162.	4.5	58
51	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
52	The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Annals of Oncology, 2016, 27, 1174-1177.	1.2	53
53	Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	2.8	53
54	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer, 2016, 61, 111-121.	2.8	51

#	Article	IF	CITATIONS
55	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-14.	3.0	51
56	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2020, 26, 4064-4071.	7.0	50
57	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. British Journal of Cancer, 2016, 114, 889-896.	6.4	46
58	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
59	TheraP: ¹⁷⁷ Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603) Journal of Clinical Oncology, 2022, 40, 5000-5000.	1.6	44
60	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2776-2786.	6.4	42
61	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. European Journal of Cancer, 2021, 147, 74-83.	2.8	42
62	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clinical Cancer Research, 2022, 28, 1518-1530.	7.0	41
63	Prostate-specific membrane antigen theranostics. Current Opinion in Urology, 2018, 28, 197-204.	1.8	39
64	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. European Urology, 2020, 78, 148-154.	1.9	39
65	PARP Inhibitors. Drugs, 2012, 72, 1579-1590.	10.9	36
66	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 1925-1934.	7.0	36
67	Mortality due to immunotherapy related hepatitis. Journal of Hepatology, 2018, 69, 976-978.	3.7	34
68	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Reports, 2021, 34, 108585.	6.4	33
69	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021, 12, 5049.	12.8	33
70	The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment. Current Drug Targets, 2011, 12, 2034-2044.	2.1	32
71	Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer, 2012, 106, 1728-1734.	6.4	31
72	The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Journal of Cancer Survivorship, 2019, 13, 503-511.	2.9	31

#	Article	IF	CITATIONS
73	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. European Journal of Cancer, 2020, 124, 15-24.	2.8	31
74	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. European Urology Focus, 2021, 7, 234-237.	3.1	31
75	HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine. Current Drug Targets, 2011, 12, 2045-2058.	2.1	30
76	Recent Insights and Advances in the Management of Merkel Cell Carcinoma. Journal of Oncology Practice, 2016, 12, 637-646.	2.5	30
77	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clinical Cancer Research, 2017, 23, 6070-6077.	7.0	30
78	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
79	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. SLAS Discovery, 2021, 26, 1107-1124.	2.7	30
80	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. Clinical Cancer Research, 2011, 17, 5188-5196.	7.0	29
81	Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. Journal of Clinical Pharmacology, 2013, 53, 1020-1027.	2.0	29
82	Bevacizumab as a steroidâ€sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Science Reports, 2019, 2, e115.	1.5	29
83	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 C 837-846.	0.784314 r 1.6	gBT /Over o 29
84	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) Journal of Clinical Oncology, 2022, 40, LBA5004-LBA5004.	1.6	29
85	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	1.9	28
86	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 2020, 30, 261-267.	1.2	27
87	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. European Urology Focus, 2022, 8, 1157-1168.	3.1	26
88	E6AP promotes prostate cancer by reducing p27 expression. Oncotarget, 2017, 8, 42939-42948.	1.8	25
89	18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors. PET Clinics, 2020, 15, 11-22.	3.0	22
90	γδT Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. Cancer Immunology Research, 2021, 9, 612-623.	3.4	22

#	Article	IF	CITATIONS
91	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Neoplasia, 2019, 21, 389-400.	5.3	20
92	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology, 2020, 16, 2165-2175.	2.4	20
93	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma Journal of Clinical Oncology, 2022, 40, TPS9605-TPS9605.	1.6	19
94	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. British Journal of Cancer, 2013, 109, 1079-1084.	6.4	18
95	Genomic Analysis of Circulating Tumor DNAÂUsing a Melanoma-Specific UltraSEEK Oncogene Panel. Journal of Molecular Diagnostics, 2019, 21, 418-426.	2.8	18
96	Efficacy of immune checkpoint inhibitors for in-transit melanoma. , 2020, 8, e000440.		18
97	ENZAâ€p trial protocol: a randomized phase II trial using prostateâ€specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castrationa€resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 2021, 128, 642-651.	2.5	18
98	Relevance of DNA damage repair in the management of prostate cancer. Current Problems in Cancer, 2017, 41, 287-301.	2.0	16
99	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	2.3	16
100	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. Clinical Genitourinary Cancer, 2021, 19, e200-e205.	1.9	16
101	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. Cancer Cell, 2011, 19, 573-574.	16.8	15
102	Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. Investigational New Drugs, 2020, 38, 844-854.	2.6	15
103	PRINCE: Phase I trial of ¹⁷⁷ Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2022, 40, 5017-5017.	1.6	15
104	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 312-319.	1.1	13
105	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the â€~Australian guidelines for the management of cutaneous melanoma'. Australasian Journal of Dermatology, 2017, 58, 274-277.	0.7	12
106	Establishing a cryopreservation protocol for patientâ€derived xenografts of prostate cancer. Prostate, 2019, 79, 1326-1337.	2.3	12
107	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	2.8	12
108	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. IScience, 2019, 22, 1-15.	4.1	11

#	Article	IF	CITATIONS
109	Patient-reported outcomes in melanoma survivors at 1, 3 and 5Âyears post-diagnosis: a population-based cross-sectional study. Quality of Life Research, 2020, 29, 2021-2027.	3.1	11
110	Integration of Immuno-Oncology and Palliative Care. Journal of Clinical Oncology, 2016, 34, 1561-1562.	1.6	10
111	[177 Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply. Lancet Oncology, The, 2018, 19, e373.	10.7	10
112	Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. BMC Medical Genomics, 2019, 12, 115.	1.5	10
113	The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology, 2017, 71, 748-749.	1.9	9
114	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers, 2021, 13, 2334.	3.7	9
115	CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2021, 20, 2140-2150.	4.1	9
116	Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. European Urology, 2019, 75, 927-928.	1.9	8
117	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. , 2020, 8, e000700.		8
118	i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol. BMJ Open, 2020, 10, e036059.	1.9	8
119	Microbiome transplantation and modulation of immune related adverse events. EClinicalMedicine, 2019, 8, 10-11.	7.1	7
120	Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
121	Use of vemurafenib in a patient unable to swallow whole. Journal of Oncology Pharmacy Practice, 2016, 22, 733-737.	0.9	6
122	Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. , 2022, 10, e004574.		6
123	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Investigational New Drugs, 2022, 40, 1051-1065.	2.6	4
124	Toward a Better Dialogue Between Neuro-Oncologists and Phase I Investigators. Journal of Clinical Oncology, 2012, 30, 562-563.	1.6	3
125	DETECTION phase II/III trial: Circulating tumor DNA–guided therapy for stage IIB/C melanoma after surgical resection Journal of Clinical Oncology, 2022, 40, TPS9603-TPS9603. 	1.6	3
126	Practical Polling for Prostate Cancer: AR-V7–based Treatment Selection. European Urology, 2017, 71, 883-885.	1.9	2

#	Article	IF	CITATIONS
127	Reply to M. Horiguchi et al. Journal of Clinical Oncology, 2018, 36, 722-723.	1.6	2
128	Molecular classification of hormoneâ€sensitive and castrationâ€resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. Prostate, 2022, 82, 993-1002.	2.3	2
129	Reply: â€~Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. British Journal of Cancer, 2014, 110, 267-268.	6.4	1
130	Reply to E. Hindié. Journal of Clinical Oncology, 2021, 39, 944-946.	1.6	1
131	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷ Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2022, 40, 5027-5027.	1.6	1